FDA approves FC2 female condom

The Female Health Company on Wednesday announced that FDA has approved its FC2 Female Condom to help prevent pregnancy and sexually transmitted infections such as HIV, the AP/Forbes reports.

With the approval, the lower-cost, new version of the female condom now will be available in the U.S. In addition, USAID now can procure the condoms and distribute them through HIV/AIDS programs worldwide (AP/Forbes, 3/11).

The new female condom is made of synthetic rubber instead of polyurethane and is less expensive than the original version. According to the Chicago Tribune's "Triage," both the new version and older version are equally effective. The new version likely will cost about 30% less than the older version, making it more affordable for individuals and public health groups, Mary Ann Leeper, strategic adviser to FHC, said (Graham, "Triage," Chicago Tribune, 3/11). The new version also is manufactured through a less-expensive process, which FHC said should allow health groups to distribute larger quantities to women in Africa and other areas heavily affected by HIV/AIDS. The FDA approval is an "important development in efforts to deliver affordable access to woman-initiated HIV prevention in the United States and around the world," Leeper said (Reuters India, 3/11).

The World Health Organization in 2006 approved the new version of the female condom for purchase by United Nations agencies, according to FHC. More than 23 million FC2 condoms have been distributed in 77 countries since then (AP/Forbes, 3/11).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Historical redlining continues to affect HIV treatment in affected communities